A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.
Epistemonikos ID: 8db3e755d60ecbeb91514bad1e1cf71e91eaf72e
First added on: May 31, 2025